Pay in 4 interest-free payments of $6.92 Learn more
Ships within 48 hours · Estimated delivery Sep 4 - Sep 9
The dawn of the age of amino acid sensors for the mTORC1 pathway
Burbrink, Frank T
Regeneron presented Phase II/III data in its application for regulatory approval showing rapid and sustained normalization of albumin, one of the key markers of CHAPLE disease, in all 10 patients at 24 weeks
Multiple animal models and clinical trials have demonstrated that A
Understanding this potential side effect helps patients and clinicians make informed decisions about treatment
US$ 26.01
US$ 21.16
US$ 20.63
US$ 29.36
US$ 26.60
US$ 27.76
